Baylor College of Medicine-ko ikertzaileekin lankidetzan egindako argitalpenak (30)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature

    Journal of Clinical Oncology, Vol. 42, Núm. 10, pp. 1124-1134

2023

  1. Circulating proteome for pulmonary nodule malignancy

    Journal of the National Cancer Institute, Vol. 115, Núm. 9, pp. 1060-1070

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  3. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

  4. Neurocognitive outcomes in pediatric brain tumors after treatment with proton versus photon radiation: a systematic review and meta-analysis

    World Journal of Pediatrics, Vol. 19, Núm. 8, pp. 727-740

  5. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

    Circulation: Heart Failure, Vol. 16, Núm. 5, pp. E009694

2022

  1. Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease

    Respiratory Research, Vol. 23, Núm. 1

  2. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement

    Obesity Facts, Vol. 15, Núm. 3, pp. 321-335

  3. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement

    Clinical Nutrition, Vol. 41, Núm. 4, pp. 990-1000

  4. Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: Cui bono ?

    Gut

  5. Lung Spatial Profiling Reveals a T Cell Signature in COPD Patients with Fatal SARS-CoV-2 Infection

    Cells, Vol. 11, Núm. 12

  6. Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 476-488

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. Worldwide barriers to genetic testing for movement disorders

    European Journal of Neurology, Vol. 28, Núm. 6, pp. 1901-1909

2020

  1. Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial

    Journal of Clinical Oncology, Vol. 38, Núm. 11, pp. 1186-1197

2019

  1. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Congenital Uterine Malformation by Experts (CUME): better criteria for distinguishing between normal/arcuate and septate uterus?

    Ultrasound in Obstetrics and Gynecology, Vol. 51, Núm. 1, pp. 101-109